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CASE PRESENTATION
A 36-year-old man was referred to the nephrology
clinic at the University Hospital of Alcala´ de Henares
because of an incipient uremic syndrome.
He had been included in a hemodialysis program due
to terminal chronic renal failure on the basis of right re-
nal agenesis, left reflux nephropathy, and possible focal
glomerulosclerosis. After 5 years in the dialysis program,
he received a cadaveric kidney transplant. The graft never
completely functioned normally, but the serum creatinine
remained at 2 mg/dL. During the following years, the pa-
tient’s clinical evolution was considered acceptable; he
had no relevant clinical problems. Immunosuppression
consisted of prednisone, cyclosporine (CsA), and my-
cophenolate mofetil. Renal function slowly and gradu-
ally decreased; the dysfunction was attributed to chronic
nephropathy of the graft itself. Blood pressure levels dur-
ing this period were slightly elevated but could be man-
aged with enalapril, 20 mg twice daily. Three months
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before admission, he presented with an episode of se-
vere gastrointestinal hemorrhage caused by bleeding of a
duodenal ulcer; the bleeding resolved with medical treat-
ment. During his admission, acute renal failure developed
and his serum creatinine reached 9.3 mg/dL but recov-
ered to basal levels of 2 mg/dL when he left the hospital.
After this episode, the patient temporarily stopped com-
ing to the transplantation center, as he had changed his
residence.
The patient was admitted to the hospital with asthenia,
easy fatigability, occasional morning nausea, pruritus, and
cramps in his lower limbs. He also presented with dyspnea
on effort and occasional migraine. The patient had lost 15
kg since his last visit, and his weight had stabilized since.
His treatment comprised prednisone, 10 mg/day; CsA,
150 mg twice daily; mycophenolate mofetil, 500 mg twice
daily; enalapril, 20 mg twice daily; erythropoietin, 4000
units/week; omeprazole, 20 mg/day; calcium carbonate, 1
g/8 hours with meals; calcitriol, 0.25 lg/day; and sucral-
fate, 1 g/6 hours. Physical examination disclosed a systolic
heart murmur, moderate pulmonary crackles, moderate
malleolar edema, and a blood pressure of 210/130 mm
Hg.
Blood analysis showed hemoglobin, 10.3 g/dL, with
normal leukocyte and platelet counts; serum creatinine,
8.6 mg/dL; urea, 201 mg/dL; phosphorus, 5.7 mg/dL; and
uric acid, 11.3 mg/dL; the rest of the blood parameters
were normal. Twenty-four–hour urine protein excretion
was 0.9 g, and the creatinine clearance 9 mL/min. Blood
cyclosporine level was 394 ng/mL. A chest radiograph
revealed interstitial bilateral edema.
The presence of severe arterial hypertension and signs
of incipient heart failure prompted intravenous adminis-
tration of furosemide and calcium antagonists. The CsA
dosage was reduced, and blood levels showed progres-
sive reduction. Hypertension was controlled, and the
patient’s general status improved. One week later, his
blood pressure was 130/80 mm Hg, lung auscultation was
clear, and the edema had disappeared. Serum creatinine
was 7.5 mg/dL and the blood CsA level was 95 ng/mL.
Furosemide and calcium antagonists were stopped as the
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patient was feeling better, blood pressure levels were nor-
mal, the serum creatinine concentration fell further to 5.9
mg/dL, and the CsA level was 132 ng/mL.
DISCUSSION
DR. SANTIAGO LAMAS (Research Professor, Centro
de Investigaciones Biologicas-Consejo Superior de In-
vestigaciones Cientificas/Group Leader at Centro Na-
cional de Investigaciones Cardiovasculares Foundation):
This patient exemplifies well how vascular complica-
tions and, more precisely, hypertension can develop after
treatment with CsA as well as the potential reversal of
both after withdrawal of the immunosupressive drug.
Calcineurin inhibitors include both CsA and
tacrolimus. Both agents share a common molecular
mechanism that is based on their ability to block the
phosphatase activity of calcineurin after they have
bound to their cellular co-effectors, cyclophillin and
FKBP (FK-506 binding protein), respectively [1–3]. This
binding in turn prevents the dephosphorylation of tran-
scription factors belonging to the NFAT family and their
translocation to the nucleus, hence leading to the absence
of NFAT-dependent gene expression, as in the case of
interleukin-2 (IL-2). Clinically, the most important side
effect associated with the use of calcineurin inhibitors
is cardiovascular toxicity [4]. The spectrum of cardio-
vascular toxicity includes hypertension, accelerated
atherosclerosis, thrombotic microangiopathy-related
syndromes, and other metabolic conditions favoring car-
diovascular disease such as dyslipidemia and diabetes.
By far the most important of these is hypertension.
This secondary effect and its pathophysiologic basis,
particularly at the cellular level, will constitute the core
of my discussion.
Since the introduction of CsA as an immunosuppres-
sant in the early 1980s, one of the most compromising side
effects affecting the outcome of transplantation has been
hypertension. Although post-transplant hypertension is
very common (occurring in more than 80% of patients)
and multifactorial, it seems clear that immunosuppres-
sive drugs play a significant role [5]. The combination of
steroids and calcineurin inhibitors especially contributes
to this situation.
Endothelial dysfunction as an essential mechanism in-
volved in hypertension associated with the use of cal-
cineurin inhibitors
As most studies have been performed with CsA rather
than with tacrolimus, I will primarily refer to the former.
The essential cornerstone in the development of CsA-
mediated hypertension seems to be an increase in vas-
cular resistance [5]. Table 1 lists the toxic effects of cy-
closporine A and Table 2 pathogenetic mechanisms in-
voked to explain this increase in vascular resistance.
Table 1. Toxic effects of cyclosporine A
Renal Tubulointerstitial fibrosis, tubular atrophy
Vascular Endothelial dysfunction, atherosclerosis,
thrombotic microangiopathy
Hepatic Steatosis, changes in endoplasmic reticulum
Nervous system Tremors, convulsions, encephalopathy
Oncogenesis Increased tumor formation
Metabolic Dyslipidema, diabetes
Table 2. Proposed mediators for vascular dysfunction
Sympathetic overactivity
Relative deficiency of nitric oxide
Transforming growth factor-b1
Endothelin-1
Reactive oxygen and nitrogen species
Vasoconstrictor eicosanoids
Although sympathetic overactivity might act as a
pathogenetic factor, studies in humans suggest that im-
pairment of vasodilation is not related to sympathetic
overactivity [6]. Studies done more than a decade ago in
cultured smooth muscle or mesangial cells proposed in-
creased contractility in cells exposed to CsA [7, 8]. How-
ever, in recent years it has become evident that a central
problem underlying the increase in vascular resistance
produced by CsA is endothelial dysfunction. I would like
to look in some detail at this condition.
Endothelial dysfunction can be defined as a derange-
ment of normal endothelial function and disordered reg-
ulation of vascular tone; the term also includes problems
of platelet aggregation and failure of maintenance of a
biocompatible surface for blood flow. Endothelial dys-
function is not easy to study from a clinical standpoint,
but the best test available is the ability of arteries to di-
late in response to an endothelial nitric oxide synthase
(eNOS) agonist such as acetylcholine [9]. The relaxation
state can be controlled either in an invasive manner or by
noninvasive means such as plethysmography [10]. Several
studies using these techniques have provided data in pa-
tients treated with CsA that are consistent with intrinsic
endothelial dysfunction [11–13]. In these studies, impair-
ment in endothelial-dependent vasodilation was a uni-
versal feature, in contrast with endothelium-independent
vasodilation, which remained similar both in patient and
control groups. As endothelial dysfunction is fundamen-
tally related to a disturbance in the L-arginine-nitric oxide
(NO)-cyclic guanosine monophosphate (cGMP) path-
way, it seems pertinent to discuss the knowledge accu-
mulated on this issue.
Early in the course of pathophysiologic studies, a lack
of NO [14] or a deficient L-arginine-NO-cGMP path-
way [15–17] were suggested as potential causes for the
endothelial dysfunction associated with CsA. Studies in
experimental models including “ex vivo” isolation of ar-
teries and organ bath preparations seemed to confirm
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Fig. 1. Increased expression of endothelial nitric oxide synthase
(eNOS) in endothelial cells. The figure depicts a representative North-
ern analysis of eNOS mRNA expression in bovine aortic endothelial
cells (BAEC) exposed to cyclosporine A (CsA) for the indicated times.
Shown also is the 28S ribosomal RNA.
these results [18]. However, these observations con-
tradicted results at the molecular level from our own
laboratory. We observed moderate increases in eNOS ex-
pression and NO production in endothelial cells exposed
to CsA (Fig. 1) [19]. Our observations also were in ac-
cord with in vivo measurement of NO levels in humans
[20] and eNOS expression in CsA-treated patients [21].
In fact, vasoconstrictor responses could be explained by
the increase in blood pressure itself, as it may occur in
other forms of secondary hypertension [22]. Thus, while
overwhelming evidence implies endothelial dysfunction
and NO disturbance in CsA-associated hypertension, no
strong data support the notion of eNOS deficiency or lack
of activity either in vitro or in vivo.
Of interest, early evidence provided by studies in
isolated arteries and their relaxation capacity in organ
baths suggested that superoxide anion production was
increased in the presence of CsA [23]. When trying to
address the molecular mechanism of eNOS upregulation
by CsA, we found that reactive oxygen species (ROS)
were involved [24] and suggested that the presence of
superoxide might decrease NO availability, as had been
shown even before the identification of endothelium-
derived relaxing factor (EDRF) as NO [25], thus rec-
onciling animal and molecular studies. This notion has
started to prevail and is now accepted by other inves-
tigators [21, 26]. Our laboratory has gained insight into
the molecular mechanisms by which CsA up-regulates
eNOS. We found that the mechanism was mainly tran-
scriptional and involved the transcription factor ac-
tivator protein-1 (AP-1), thus providing a link with
the generation of ROS, which are capable of activating
this pathway [27, 28]. In a recent study performed in kid-
ney transplant patients treated with CsA or tacrolimus,
the up-regulation of eNOS mRNA was confirmed, as well
as the up-regulation of p22phox and transforming growth
factor-b (TGF-b) [29]. This same study also demon-
strated the presence of oxidative stress and its partial
reduction with ramipril.
Peroxynitrite formation in endothelial cells as a conse-
quence of exposure to CsA
Even though CsA-induced endothelial cell injury was
reported nearly two decades ago [30], few studies have
addressed the cellular mechanisms leading to it. Because
our data were consistent with an increased production of
superoxide and NO after 8 to 24 hours of exposure of en-
dothelial cells to CsA, we explored the formation of NO
after short exposures to CsA using several approaches.
Detection of ROS and nitrogen species in vascular cells
or tissues is challenging, and thus the combination of two
or more methods for each radical species is recommended
[31]. In endothelial cells exposed for 2 hours to CsA 10−6
mol/L, we were able to show intracellular formation of
NO and superoxide (Figs. 2 and 3) [32].
As is well known, spatiotemporal coincidence of super-
oxide and NO can lead to the nonenzymatic formation of
peroxynitrite (ONOO−). The use of fluorescent probes
with specificity for each ROS or nitrogen species together
with other complementary approaches was extremely
useful (Fig. 4) [32, 33]. Peroxynitrite is a nonradical,
highly reactive nitrogen species that is now recognized as
a major mediator of NO’s effects [34]. Protein tyrosine ni-
tration has been established as a consequence and molec-
ular footprint of peroxynitrite formation, even when the
nitration reaction does not directly follow interaction of
tyrosine groups with peroxynitrite but rather with its rad-
ical products [35]. Even when nitration yields of proteins
in vivo are low, the occurrence of peroxynitrite can mod-
ify protein function, and its presence has been correlated
with disease states such as coronary atherosclerosis [36]
and neurologic disease [37]. Using immunocytochemical
techniques, we detected in endothelial cells an augmented
presence of nitrotyrosine staining, which was reduced by
the presence of N-acetylcysteine (NAC), a glutathione
donor and radical scavenger employed in the clinical set-
ting for acetaminophen intoxication (Fig. 5) [32].
Further work from our laboratory has provided evi-
dence about the limiting role of the superoxide species
in the formation of peroxynitrite during CsA treatment.
In particular, we identified superoxide anion and not NO
as the limiting factor for the formation of peroxynitrite
not only when it was generated by chemical means but
also when cells were exposed to high glucose levels in
the presence of CsA [38]. Work in progress in our lab-
oratory has allowed us to identify target proteins that
become nitrated by CsA. I now would like to discuss our
preliminary work on the role of manganese superoxide
dismutase (MnSOD) that I am carrying out with my col-
leagues, Javier Navarro-Antolı´n and Mariano Redondo-
Horcajo. Nitration of MnSOD might represent an impor-
tant additional mechanism for CsA-associated vascular
injury, as MnSOD is present in post-transplant renal allo-
grafts, and its function is inactivated by nitration [39]. This
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Fig. 2. Extracellular nitric oxide (NO) is in-
creased in bovine aortic endothelial cells
(BAEC). NO chemiluminescence signal and
nitrite accumulation are increased in cells ex-
posed to cyclosporine A (CsA) for short peri-
ods, thus implying an activation of the enzyme.
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Fig. 3. Intracellular formation of superoxide is increased by the presence of cyclosporine A (CsA). The fluorescence intensity of dihydroethidine
is increased by the presence of CsA and the superoxide generator DMNQ (2,3-dimethoxy-1,4-haptoquinore) in bovine aortic endothelial cells
(BAEC), as evaluated by flow cytometry.
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Fig. 4. Cyclosporine A (CsA) causes peroxynitrite production in bovine aortic endothelial cells (BAEC). The spatiotemporal coincidence of nitric
oxide (NO) and O2− leads to peroxynitrite formation. This might be detected by an increased fluorescence intensity of dihydrorhodamine 123. Both
the peroxynitrite generator SIN-1 (3-morpholinosydnonimine) and pure peroxynitrite give strong fluorescence, whereas inactivated peroxynitrite,
hydrogen peroxide, the NO donor DEA-NO (diethylamine NoNOate) and DMNQ are comparable to control.
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Fig. 5. Tyrosine nitration is increased in bovine aortic endothelial cells (BAEC). Immunodetection of tyrosine nitration is increased in BAEC
treated with cyclosporine A (CsA) and SIN-1. The reaction is abrogated by the permeable manganese superoxide dismutase (MnSOD) analogue
MnTMPyP and the antioxidant N-acetylcysteine (NAC) and competed by 3-nitrotyrosine.
inactivation might be related to nitration of critical tyro-
sine residues, but also to tyrosine oxidation and dityro-
sine formation [40]. Studies in mice treated with CsA
or a combination of CsA and NAC demonstrated an
increase in tyrosine nitration in the vascular wall, thus
also proving the presence of tyrosine nitration “in vivo.”
Nitration of MnSOD also has been documented in rat
kidneys infused with angiotensin II [41]. The produc-
tion of peroxynitrite and increased nitrotyrosine levels
in response to CsA has also been observed in other cell
types such as porcine kidney proximal tubule cells [42].
This generation of superoxide was proposed to be medi-
ated by dihydronicotinamide adenine dinucleotide phos-
phate (NADPH) oxidase activation, and the disruption of
the bradykinin/cGMP pathway could represent a conse-
quence of superoxide excess. Overall, these studies lend
credence to the concept that peroxynitrite constitutes a
general mechanism for the cellular toxicity associated
with CsA. As CsA has been related to the genesis of
accelerated atherosclerosis [43], it is tempting to specu-
late that peroxynitrite formation and tyrosine nitration
contribute to this clinical problem.
Endothelin-1 as a mediator of CsA-related
vascular injury
Studies in the early 1990s in endothelial cell cultures
exposed to CsA revealed an increase in the synthesis of
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endothelin-1 (ET-1), a powerful vasoconstrictor peptide
[44]. This effect, likely related to an increase in mRNA,
has been confirmed in mesenteric arteries of hyperten-
sive rats [45] even when other studies failed to find a
relevant role for endothelin-mediated vasoconstriction
in renal vessels [46]. In rats receiving chronic CsA treat-
ment, not only the mRNA for pre-proET-1 but also that
of endothelin-converting enzyme (ECE) were increased
[47]. Thus, increases in ET-1 might be a pathogenetic
mechanism leading to CsA-associated hypertension. The
potential importance of ROS also was highlighted in one
study in isolated arteries in which ET-1 mediated super-
oxide production [26]. ET-1 also might be involved in
microvascular dysfunction promoted by CsA [48] and, in
fact, the blockage of ET-B receptors seems to improve
this condition in an experimental model of angiogenesis
[49].
Intracellular targets for calcineurin inhibitors and their
relevance for endothelial injury
One of the issues that remains unsolved relates to the
intracellular mechanisms that lead to the triggering of
endothelial cell damage. Aside from our data regard-
ing the production of peroxynitrite, other investigators
have studied a number of intracellular targets for CsA
in endothelial cells. Longoni et al observed increased
apoptosis in cultured human endothelial cells with high
doses of CsA. However, therapeutic doses imposed an
up-regulation of the antiapoptotic molecule Bcl-2 [50].
This up-regulation was related to the production of low
levels of ROS. This increase also was observed in smooth
muscle cells promoting DNA synthesis in a process in-
volving cytochrome P-450 metabolism of CsA [51]. In
fact, the cytochrome P-450 system was suggested as a
generator of oxygen radicals more than a decade ago
[52].
Interestingly, some investigators have found that low
doses of CsA might have a cytoprotective effect in en-
dothelial cells and linked this possibility to the role of
vascular endothelial cell growth factor (VEGF) [53].
Caramelo et al et al believe that the binding of CsA to
cyclophillin, its intracellular partner, is the key event lead-
ing to toxicity, and suggest that calcineurin inhibition is
not an essential feature of endothelial damage [54]. The
role of VEGF as a protective agent in CsA-associated
vascular toxicity is supported by studies in animal models
and other cell types [55]. Studies have shown that CsA
inhibits VEGF-dependent angiogenesis in endothelium
through a cyclo-oxygenase-2 (COX-2)–mediated mech-
anism [56]. Even though prostacyclin inhibition was ini-
tially linked to microvascular endothelial damage [57], its
relevance is likely to be more important in nephrotoxicity
than in endothelial/vascular toxicity associated with the
use of CsA.
Cyclosporine versus tacrolimus: Do they differ in vascular
toxicity?
I believe we still do not have a definitive answer
to this question. One study found no significant differ-
ences regarding the degree of endothelial dysfunction
[12]. This study was performed in renal transplant recipi-
ents and included monitoring of endothelial function us-
ing high-resolution brachial ultrasonography. However,
in another report, conversion of patients from CsA to
a tacrolimus-based regime significantly lowered blood
pressure and reduced cardiovascular risk [58]. The in-
troduction of newer immunosuppressive agents such as
mycophenolate mofetil and rapamycin has fostered stud-
ies regarding cardiovascular toxicity of these agents in
comparison with CsA or tacrolimus. In one of these stud-
ies undertaken in porcine epicardial coronary arteries,
endothelial-dependent relaxation was clearly compro-
mised with all four agents; tacrolimus and rapamycin
showed even greater impairment at lower doses [59]. I
have not discussed management of the clinical problem
of CsA-induced nephrotoxicity and the methods of deal-
ing with that vexing issue. I would refer you to recent pa-
pers that have dealt directly with that issue [60]. Clearly,
more studies are needed from both the pathophysiologic
and clinical standpoints.
In summary, calcineurin inhibitors produce vascular
toxicity in patients with post-transplant hypertension.
There seems to be agreement that endothelial dysfunc-
tion is a distinctive pathophysiologic feature of vascular
toxicity. Moreover, there is no defect in NO synthesis, but
rather an increased degradation of this mediator, prob-
ably because of superoxide and eventual peroxynitrite
formation. Tyrosine nitration constitutes an appealing
mechanism that might lead to our finding valuable ther-
apeutic targets.
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Division of Nephrology,
Tufts-New England Medical Center, Boston, Massachus-
setts): Nephropathy induced by CsA is seen both in nonre-
nal transplant patients with an intact sympathetic nervous
system and in renal transplant patients who do not have
an intact sympathetic system. Can we learn anything from
an examination of patients in these disparate groups?
DR. LAMAS: Initial studies suggested that sympathetic
reactivity could be important for blood pressure elevation
related to CsA treatment. However, studies done in grafts
that are actually denervated, and therefore devoid of the
action of adrenergic mediators, showed that hypertension
can occur as a side effect. In addition, studies looking at ex
vivo vessels exposed to CsA in organ baths confirmed that
sympathetic overactivity is not a fundamental mechanism
associated with CsA blood pressure elevation [6].
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DR. FRANCESCO P. SCHENA (Chief of Renal Unit, Uni-
versity of Bari, Italy): In your presentation, you showed
an in vitro study indicating that high glucose concen-
tration plus CsA increased peroxynitrite production by
endothelial cells. Do you believe that we should stop giv-
ing CsA to patients with post-transplantation diabetes
mellitus because high glucose levels and CsA can induce
peroxynitrite and therefore accelerate atherosclerosis?
DR. LAMAS: Not enough data in the literature sup-
port such a strong recommendation. I believe that in
some cases the interruption of CsA treatment will help
defer vascular injury promoted by diabetes. But this
raises an important issue related to potential therapeutic
prevention of this injury. Our experimental data suggest
that antioxidants might be useful. Large clinical studies
with antioxidants such as glutathione donors have not
been conducted for this purpose, even when they seem
appropriate.
DR. CLAUDIO PONTICELLI (Retired Director, Renal
Unit, Ospedale Maggiore, Milano): In clinical practice,
nephrotoxicity caused by CsA is mainly dose-dependent.
You showed that peroxynitrite formation is increased
even when CsA blood levels are in the normal range.
However, peroxynitrite production was lower when CsA
blood levels were low. Perhaps giving low doses of CsA,
which is now possible by combining CsA with other im-
munosuppressive drugs, can prevent nephrotoxicity and
vascular toxicity.
DR. LAMAS: I think this is a crucial point. The lev-
els of peroxynitrite have been detected with the concen-
trations and the doses I already mentioned. One of our
concerns is whether this could be extrapolated to the clin-
ical setting. Even when there is some overlap between
the concentrations of CsA leading to peroxynitrite for-
mation and the concentrations we find in patients, it is
clear that we still do not know the yield of peroxyni-
trite formation in humans. Moreover, the targets for tyro-
sine nitration in humans remain largely unknown. Many
studies, probably using proteomic approaches, need to
be done to identify nitrated proteins in humans exposed
to CsA. We know that the yield of nitrated proteins is
low, but the pathophysiologic importance is high. How-
ever, as you said, we can probably titrate the produc-
tion of peroxynitrite just by reducing the levels of CsA.
What I wanted to highlight is that the pathogenetic
mechanisms, not only for vascular toxicity, but also for
side effects associated with CsA in other organs, might
be related to the specific nitration of yet-unidentified
proteins.
DR. JOHN FEEHALLY (Professor of Renal Medicine,
The John Walls Renal Unit, Leicester General Hospital,
UK): Given in vivo, CsA evokes significant differences in
the responses among species, for example, rats compared
to humans. You discussed data from rat and human renal
cells, and bovine endothelial cells, as well as data from rat
resistance vessels. Are there limitations in extrapolating
such data to humans?
DR. LAMAS: Most of the studies in our laboratory have
employed bovine aortic endothelial cells. In some cases
we used human umbilical vein endothelial cells, and ba-
sically we have the same kind of observations. But re-
garding the relevance of the studies of the experimental
models, what is most important is that CsA elevates the
synthesis of NO and of superoxide anion in vivo in human
vessels and cells [20, 61].
DR. JOSE´ LUIS RODICIO (Chief, Department of
Nephrology, Hospital 12 de Octubre, Madrid, Spain):
Does tacrolimus have the same effects as CsA on vas-
cular injury? Are prostaglandin-related species involved
in vascular injury?
DR. LAMAS: The experimental models that we have
been using do not show fundamental differences between
tacrolimus and CsA regarding endothelial dysfunction.
Some clinical studies have reported that tacrolimus is
associated with reduced cardiovascular events and also
a decreased incidence of elevated blood pressure [58],
even when post-transplant hypertension occurs. As to
your second question, most of the studies suggest that
prostaglandins are not involved in the vascular toxicity.
However, the role of prostaglandins in the renal toxicity
associated with CsA is tremendously important, and this
is probably due to the effect of calcineurin inhibitors on
tubular cells. So we need to be very careful when we are
looking at CsA-induced nephrotoxicity, as it is a different
problem from vascular toxicity.
DR. HARRINGTON: Is it theoretically possible to
block the protein nitration effect of CsA in vivo with-
out blocking the desired immunosuppressive effect of
CsA?
DR. LAMAS: This is an important issue. Currently, an
excess in protein nitration has been associated with neu-
rodegenerative diseases such as amyotrophic lateral scle-
rosis, which is in some familial cases due to mutations in
the Cu,Zn SOD gene [62]. Thus an interest in blocking
nitration has arisen from a different field. In theory, an-
tioxidants such as NAC could inhibit or retard nitration,
but I am not aware of any clinical data. Strategies aimed
at the development of drugs or peptides that could act
as sinks for nitration, therefore competing with endoge-
nous tyrosines (which are crucial targets for alteration of
protein function), should be pursued.
DR. MAHBOOB LESSANPERESHKI (Associate Profes-
sor of Internal Medicine and Nephrology, Tehran Univer-
sity of Medical Science, Tehran, Iran): Is there any differ-
ence between acute and chronic CsA toxicity and vascular
damage in terms of the implication of TGF-b?
DR. LAMAS: Most studies involving TGF-b and CsA
toxicity are related to renal injury rather than vascu-
lar toxicity, and this cytokine has been shown to be
an important pathogenetic agent in chronic exposure
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to CsA. Acute vascular toxicity is directly related to a
disequilibrium in vasoactive factors that leads to endothe-
lial dysfunction.
DR. PONTICELLI: Whenever there is an overproduc-
tion of ROS, there is an activation of antioxidant mech-
anisms, and usually this maintains a balance. Low-dose
CsA produces a relatively mild overproduction of ROS,
so it should be easy to maintain a balance in our organism.
What is your feeling about that?
DR. LAMAS: I agree. It is important to keep in mind
that ROS are not only considered to be “bad guys”; they
are also physiologic mediators. Hence, the complete ab-
rogation of ROS would certainly put us in very bad shape.
As you said, it is important to keep a balance. The point
is the spatiotemporal coincidence and the concentrations
that we might find inside cells at specific moments. Pos-
sibly, in the initial stages after transplantation, patients
are exposed to high concentrations of CsA, and reactive
oxygen and nitrogen intermediates are produced. These
are the crucial moments in which peroxynitrite might be
harmful.
DR. RAJEEV ANNIGERI (Consultant Nephrologist,
Apollo Hospitals, Chennai, India): What is the interaction
of angiotensin blockade with CsA toxicity in the kidney?
DR. LAMAS: The drug type of choice for treat-
ment of post-transplant hypertension is the angiotensin-
converting-enzyme antagonist. The synthesis of ROS has
also been observed with angiotensin II, so clearly an-
giotensin II contributes to endothelial dysfunction in the
context of CsA treatment [63].
DR. MANUEL MARTINEZ–MALDONADO (President
and Dean, Ponce School of Medicine, Ponce, Puerto Rico):
My question also relates to the role of angiotensin II. It
seems that most of the studies you have done show an
acute effect of CsA on cells through either the produc-
tion of peroxynitrite or through oxygen radicals. As you
mentioned, angiotensin II can do this also. The question
is, is this effect an immediate cause of the endothelial
dysfunction? Later, as endothelial dysfunction is main-
tained, does a combination of salt and water retention
and local angiotensin II activation sustain the blood
pressure?
DR. LAMAS: Few studies in experimental models have
looked at the involvement of angiotensin II in CsA-
mediated hypertension, but they have been recently re-
viewed [64]. The scenario of ROS being boosted by
the presence of angiotensin II and CsA is highly prob-
able. The amelioriation of post-transplant hyperten-
sion attributed to CsA is evident when angiotensin II
receptor antagonists or angiotensin-converting-enzyme
activity blockers are used. Even from the pathogenetic
point of view, I do not have a definitive answer to your
question. The mechanism you propose is very attractive.
DR. SHAHRZAD SHAHIDI (Nephrologist, Noor Hospi-
tal, Esfahan, Iran): What is your opinion about continuing
to give calcium channel blockers even after correction of
blood pressure in the case presented?
DR. LAMAS: Calcium channel antagonists such as
nifedipine or amlodipine are adequate drugs for correct-
ing post-transplant hypertension associated with the use
of CsA. I am not aware of any study showing a patho-
genetic or harmful effect derived from their use in this
context. The continuation of their use in the case at hand
would depend on blood pressure levels and the appear-
ance of any undesirable side effect, although probably
monitoring CsA levels was the most important therapeu-
tic maneuver in this case.
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